Dhingra Ashwani K, Chopra Bhawna, Rathi Vaibhav, Sapra Sameer
Guru Gobind Singh College of Pharmacy, Yamuna Nagar-135001, Haryana, India.
Quantum School of Health Sciences, Quantum University, Roorkee-247167, Uttarakhand, India.
Curr Drug Discov Technol. 2023;20(2):e171022210062. doi: 10.2174/1570163820666221017111556.
COVID-19, aka Coronavirus Disease 2019, triggered by new severe acute respiratory syndrome coronavirus-2 or SARS-CoV-2, is now a public health emergency due to its rapid spread, high transmission efficiency, and severe viral pandemic that is significantly increasing the number of patients and associated deaths. Currently, no specific treatment is available for this highly contagious virus. The unavailability of effective and specific treatments and the severity of this epidemic situation potentiate medicinal chemists' in supporting new prophylactic or therapeutic interventions against COVID-19. This study discusses the therapeutic potential of hesperidin, a traditionally used herbal medicine with an exceptional safety profile. Recent studies on hesperidin advocate its promising potential in the prevention and management of COVID-19. This paper also discusses the recent clinical studies based on the previously documented antiviral activity of hesperidin. Herein, we propose the detailed preclinical and clinical manifestations of hesperidin based on its multifaceted bioactivities to develop a novel anti-COVID-19 lead.
2019冠状病毒病(COVID-19),又称新型冠状病毒肺炎,由新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引发,因其传播迅速、传播效率高以及严重的病毒大流行显著增加了患者数量和相关死亡人数,现已成为突发公共卫生事件。目前,针对这种高传染性病毒尚无特效治疗方法。有效和特异性治疗方法的缺乏以及疫情的严重性促使药物化学家支持针对COVID-19的新的预防或治疗干预措施。本研究讨论了橙皮苷的治疗潜力,橙皮苷是一种传统使用的草药,具有出色的安全性。最近关于橙皮苷的研究表明其在预防和管理COVID-19方面具有潜在的应用前景。本文还基于先前记录的橙皮苷抗病毒活性讨论了近期的临床研究。在此,我们基于橙皮苷的多方面生物活性提出其详细的临床前和临床表现,以开发一种新型抗COVID-19先导药物。